



ELSEVIER

Contents lists available at ScienceDirect

Annals of Hepatology

journal homepage: www.elsevier.es/annalsofhepatology

Original article

Drug-induced liver injury: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database (2004–2024)

Dongxuan Li^a, Duan Wang^b, Guili Huang^a, Qinglong Liu^a, Yalan Wang^{a,c}, Rui Zhang^{a,c}, Songqing Liu^a, Qian Du^{a,*}

^a Department of Pharmacy, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, China

^b Department of Cardiovascular Medicine, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, China

^c College of Pharmacy, Chongqing Medical University, Chongqing 400016, China



ARTICLE INFO

Article History:

Received 18 July 2025

Accepted 28 October 2025

Available online 15 November 2025

Keywords:

Drug-induced liver injury

FDA adverse event reporting system

Drug hepatotoxicity

Pharmacovigilance

ABSTRACT

Introduction and Objectives: Timely identification and discontinuation of culprit-drug is the cornerstone in managing drug-induced liver injury (DILI), and this study aims to thoroughly investigate the potential hepatotoxic drugs by using the FDA Adverse Event Reporting System (FAERS) database.

Materials and Methods: DILI-related reports in the FAERS database between 2004 and 2024 were used to compile a reported culprit-drug list, and the single drug and drug class with the highest reporting frequency were counted accordingly. The disproportionality analysis was used to assess the DILI risk of each reported culprit-drug.

Results: 236,918 DILI-related reports were submitted to the FAERS database between 2004 and 2024, in which 1459 drugs were reported as culprit-drug. Paracetamol is the most frequently reported single drug, while antineoplastic agents are the most frequently reported drug class. 806 of 1459 drugs showed positive signals in disproportionality analysis, among which vorasidenib is the drug with the highest signal strength, followed by floxuridine, pyrazinamide, delandistrogene moxeparovec, and isoniazid. In the distribution analysis of positive signal drugs, antineoplastic agents have the largest number of positive drugs and occupy a dominant position among high-risk level drugs.

Conclusions: Our study summarized a reported culprit-drug list of DILI by comprehensively reviewing the liver injury-related reports in the FAERS database, and highlighted the prominent position of antineoplastic agents in reporting frequency, risk signal strength ranking, number of positive signal drugs, and high-risk drug distribution, suggesting that we may need to pay more attention to the liver injury risk of antineoplastic agents in clinical practice.

© 2025 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

1. Introduction

Drug-induced liver injury (DILI) refers to liver test abnormalities or hepatic dysfunction after exposure to prescription or over-the-counter medications, as well as herbal and dietary supplements [1]. DILI is a serious and potentially life-threatening condition and gradually becomes the main cause of acute liver failure worldwide [2]. The incidence of DILI is about 12.0~23.8 per 100,000 people in the general population and can reach 1~6% among hospitalized

patients [2–6]. In recent years, DILI has received increasing attention from the public and medical community, and multiple authoritative academic organizations have developed diagnosis and treatment guidelines to direct DILI clinical management [7–10]. However, due to the variety of potentially pathogenic drugs, complicated pathogenesis, and lack of specific diagnostic biomarkers and treatment methods, the clinical management of DILI is still challenging at present [11,12].

In clinical practice, timely identifying and discontinuing culprit-drugs is the main principle of DILI management [7–10], so it is necessary for medical personnel to understand the potential hepatotoxicity of drugs. Currently, there are more than 1000 drugs considered to have potential hepatotoxicity [13], among which antimicrobials, non-steroidal anti-inflammatory drugs, and herbal and dietary supplements are generally reported as the most common culprit-drugs of DILI [14]. However, although some prospective and retrospective

Abbreviations: AE, adverse event; API, application program interface; ATC, Anatomical Therapeutic Chemical; CI, confidence interval; DILI, drug-induced liver injury; FAERS, FDA Adverse Event Reporting System; IDH, isocitrate dehydrogenase; MedDRA, Medical Dictionary for Regulatory Activities; PT, Preferred Term; ROR, reporting odds ratio

* Corresponding author.

E-mail address: duqian@hospital.cqmu.edu.cn (Q. Du).

<https://doi.org/10.1016/j.aohep.2025.102156>

1665-2681/© 2025 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

studies have provided detailed DILI incidence data of involved drugs [5,15], the exact DILI risk data of most drugs are still very limited [16]. In addition, with the development and application of new drugs in recent years, new therapies such as gene therapy and novel anti-neoplastic drugs have become an increasingly important trigger for DILI in the clinic [17,18]. Therefore, it is necessary to reconfirm the liver risk characteristics of drugs and provide updated reference information for clinical management of DILI.

Pharmacovigilance is defined as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other possible drug-related problems [19]. Spontaneous reporting database, as an important pharmacovigilance data resource, can provide a direct perspective for understanding the potential toxicity risk of drugs [20]. In terms of exploring the hepatotoxicity of drugs, several previous studies have used the FDA Adverse Event Reporting System (FAERS) database, the Japanese Adverse Drug Event Report database, and the VigiBase database to summarize the liver safety profile of drugs, respectively [21–23]. However, the latest study only acquired and analyzed the data of liver injury reports before 2019 [23], which has made it difficult to reflect the current epidemic state of hepatotoxic drugs. Additionally, although the above-mentioned studies have comprehensively reviewed the liver injury reports in the target pharmacovigilance database, they only highlighted a limited number of the most frequently reported hepatotoxic drugs and the drugs with the strongest hepatotoxic risk signal [21–23]. Therefore, using spontaneous reporting databases to understand the hepatotoxicity risk of drugs is a feasible strategy, but a comprehensive landscape of hepatotoxicity associated with drugs is still lacking at present.

In this context, we investigated all the AE reports related to liver injury in the FAERS database from 2004 to 2024, compiled a comprehensive list of reported hepatotoxic drugs, and assessed the hepatotoxic risk of all reported drugs by disproportionality analysis, trying to provide updated and more comprehensive reference information for DILI clinical management from the perspective of pharmacovigilance.

2. Materials and Methods

2.1. Data source

The FAERS database is a post-marketing safety surveillance program run by the FDA, which contains post-marketing adverse event (AE) reports on drugs and therapeutic biologic products submitted by healthcare professionals, consumers, and manufacturers [24]. Currently, there are more than 19 million AE reports recorded in the FAERS database, and it maintains an annual increase of nearly 1.3 million. For each archived AE report, information such as reporting time, report sources (reporter and reporting country), patient demographic characteristics (sex and age), patient outcomes, drug information, and adverse reactions involved are recorded in a highly structured format. *openFDA* is an official project operated by the FDA that aims to index high-value, high-priority, and scalable public-access data, and AE data in the FAERS database is one of the indexed resources [25]. In this study, we used the application programming interface (API) provided by the *openFDA* platform to programmatically call and obtain report information related to liver injury.

2.2. Identifying the target reports

In the FAERS database, all the adverse reaction information involved was converted to standardized terminology called Preferred Term (PT) by using the Medical Dictionary for Regulatory Activities (MedDRA). Referring to MedDRA (version 27.0), we used drug-induced liver injury (code: 10,072,268), hepatocellular injury (code: 10,019,837), cholestatic liver injury (code: 10,067,969), mixed liver

injury (code: 10,066,758), acute hepatic failure (code:10,000,804) and some other PTs that significantly indicate hepatic failure, fibrosis and cirrhosis and other liver damage-related conditions to identify and download target reports. The 90 PTs used in this study are detailed in Table S1.

2.3. Integrating the reported etiological drugs

In order to get the potential causative drug list of DILI, we inquired and extracted the generic names of drugs recorded in the field of “patient.drug.openfda.generic_name” of each downloaded DILI report. After excluding non-primary suspected drugs, drugs with duplicated names, drugs missing generic names, and drugs with ambiguous semantics, an initial list of potential DILI-causative drugs was established. After that, the Anatomical Therapeutic Chemical (ATC) classification system was used to code drugs in the initial list, and the synonymous drugs with the same ATC code (e.g., aspirin and acetylsalicylic acid) were integrated manually to obtain the final reported DILI-causative drug list.

2.4. DILI risk signal detection

Disproportionality analysis is a kind of technology used to detect risk signals of drugs by comparing the differences between the occurrence frequency and background frequency for target drugs and target AEs [26]. In this study, we used reporting odds ratio (ROR), a classic disproportionality analysis method, to evaluate potential DILI risk of drugs. Based on the two-by-two table (Table 1), the ROR value and corresponding 95% confidence intervals (CIs) are calculated by using the following formula:

$$ROR = \frac{a/c}{b/d} = \frac{ad}{bc}, \quad (1)$$

$$95\% \text{ CI} = e^{\ln(ROR) \pm 1.96 \sqrt{\left(\frac{1}{a} + \frac{1}{b} + \frac{1}{c} + \frac{1}{d}\right)}} \quad (2)$$

For the detected signal result, a positive risk signal is defined as where there are at least three target cases (a in Table 1 ≥ 3) and the lower limit of the 95%CI is greater than 1 [27].

2.5. Distribution statistics of positive signals

For drugs with positive DILI risk signals, there may also be significant differences in signal strength between drugs. Generally, high signal intensity (high ROR value) statistically indicates the potential high DILI risk [28]. In order to distinguish the DILI risk differences between positive drugs, we ranked the ROR values of positive signal drugs and divided positive signal drugs into four risk levels (levels A, B, C, and D) according to the top 5%, 6%–20%, 21%–50%, and 51%–100% of ROR values respectively [29]. Meanwhile, based on the ATC drug classification system, we made statistics on the distribution of positive signal drugs in different drug categories.

2.6. Ethics statement

This study analyzed publicly available, de-identified data from the FDA Adverse Event Reporting System (FAERS) accessed via OpenFDA.

Table 1
Two-by-two contingency tables for disproportionality analysis.

	Drug of interest	Other drugs	Total
AE of interest	a	b	a + b
Other AEs	c	d	c + d
Total	a + c	b + d	a + b + c + d

AE, adverse event.

No human subjects were involved and no intervention was performed; therefore, institutional review board/ethics approval and informed consent were not required. Data use complied with FAERS/openFDA terms and privacy safeguards.

3. Results

3.1. General characteristics of DILI reports

During the period from January 1, 2004, to December 31, 2024, a total of 236,918 target reports related to liver injury were submitted to the FAERS database. On the whole, the number of annual reports on DILI has increased year by year and reached its highest in 2024 (Fig. 1a). In terms of reporting source, physicians (37.87%) account for the highest proportion of the reporters, and the United States (Fig. 1b), France, Japan, Canada, and China are the top five countries with the highest number of submitted reports (Fig. 1c). In terms of patients, female patients are significantly more than male patients (Fig. 1d), and the age of patients is mainly concentrated in the age group over 50 years old (Fig. 1e). With regard to patient outcomes, hospitalizations accounted for 47.17% of cases, death accounted for 20.16% of cases, and 65.33% of patients had other serious conditions (Fig. 1f).

3.2. Reported etiological drug list and corresponding reporting frequency

Due to an AE report usually involving multiple drug information records, 1,924,092 drug information records were extracted from 236,918 downloaded DILI reports. After excluding non-primary suspected drugs, drugs with duplicated names, drugs missing generic names, and drugs with ambiguous semantics, the remaining drugs make up an initial list of 1812 reported causative drugs and were

coded by the ATC classification system. Subsequently, drugs with the same ATC code were integrated manually, and a final list containing 1459 reported DILI culprit-drugs was obtained (Fig. 2a). Among them, the largest number of drugs were classified as antineoplastic agents ($n = 223$), followed by antibacterials for systemic use ($n = 74$), immunosuppressants ($n = 70$), antivirals for systemic use ($n = 69$), and psycholeptics ($n = 53$) (Fig. 2b).

Based on the final culprit-drug list and corresponding drug ATC classification code, we made statistics on the most frequently reported causative single drugs and drug classes, respectively. In single drugs, paracetamol is the most frequently reported, followed by methotrexate, paracetamol combinations excluding psycholeptics, diphenhydramine, prednisone, adalimumab, pantoprazole, atorvastatin, rituximab, and acetylsalicylic acid (Fig. 3a). In drug classes, antineoplastic agents are the most frequently reported, followed by immunosuppressants, analgesics, drugs for acid related disorders, corticosteroids for systemic use, antibacterials for systemic use, psycholeptics, psychoanaleptics, agents acting on the renin-angiotensin system, and antivirals for systemic use (Fig. 3b).

3.3. Risk signal detection result

The 1459 reported DILI culprit-drugs in the final list were combined with PTs in Table S1 to detect risk signals, respectively. The risk signal detection result of 1459 drugs was detailed in Table S2 in which 806 drugs exceeded the threshold standard and showed positive signals. Among the 806 drugs with positive signal, vorasidenib (ROR: 27.67, 95% CI: 13.91–55.05) is the drug with highest signal strength, followed by floxuridine (ROR: 19.73, 95% CI: 12.22–31.85), pyrazinamide (ROR: 16.56, 95% CI: 15.66–17.50), delandistrogene moxeparvovec (ROR: 14.47, 95% CI: 8.75–23.93), and isoniazid (ROR: 14.19, 95% CI: 13.59–14.82) (Fig. 4).




Fig. 1. The basic information and patient characteristics of 236,918 DILI-related reports. (a) Distribution of annual report quantity; (b) The occupational distribution of the submitter; (c) The top 15 reporting countries; (d) The gender distribution of patients; (e) The age distribution of patients; (f) the outcome distribution of patients.




Fig. 2. Identification and classification of reported potential hepatotoxic drugs. (a) Flowchart of reported hepatotoxic drugs identification; (b) Classification and summary of reported hepatotoxic drugs. AAP, anti-inflammatory and antirheumatic products; AARAS, agents acting on the renin-angiotensin system; ACDU, antibiotics and chemotherapeutics for dermatological use; AIAAA, antidiarrheals, intestinal antiinflammatory/antiinfective agents; ATC, Anatomical Therapeutic Chemical; BSPS, blood substitutes and perfusion solutions; CDP, Corticosteroids in dermatological preparations; DILI, drug-induced liver injury; DFGD, drugs for functional gastrointestinal disorders, GAA, gynecological antiinfectives and antiseptics; OATMP, other alimentary tract and metabolism products; ODDMSS, other drugs for disorders of the musculo-skeletal system; PHHA, pituitary and hypothalamic hormones and analogues; PTWU, preparations for treatment of wounds and ulcers; SHMGS, sex hormones and modulators of the genital system.

3.4. Distribution characteristics of positive signal drugs

According to the ranking result of signal strength of 806 drugs with positive signal, 40, 121, 242, and 403 drugs were divided into risk levels A, B, C, and D, respectively. Detailed drugs involved in each risk level can be found in Table S3. Meanwhile, based on the ATC classification system, we made statistics on the drug distribution characteristics at four signal strength levels in different drug classes (Table 2). For the 40 level A drugs, the greatest number of drugs were classified into antineoplastic agents ($n = 9$), followed by antimycobacterials ($n = 6$) and antivirals for systemic use ($n = 6$). In addition, antineoplastic agents are also the drug class with the greatest number of drugs among level B, C, and D risk level drugs. In terms of the ratio of positive drugs in different classes, 68.61% (153/223) of reported antineoplastic agents showed positive DILI risk signal, while the antimycobacterials (10/10) reached 100.00% (10/10).

4. Discussion

DILI is a potentially life-threatening drug safety problem that has attracted wide attention from gastroenterologists, pharmacologists, drug manufacturers, and regulatory agencies worldwide. Spontaneous reporting database is an important component of drug post-marketing monitoring, providing an opportunity for understanding drug safety. In this study, we comprehensively reviewed and analyzed the

AE reports related to liver injury in the FAERS database from 2004 to 2024, so as to provide the latest information for clinical practice on the potential risk of drug hepatotoxicity.

Compared with previous studies using spontaneous report databases to explore drug hepatotoxicity, our study has the following advantages. First, our study used the latest updated annual AE report data in the FAERS database, which is at least five years ahead compared to other similar studies and can better reflect the current landscape of DILI in the real world [21–23]. Second, our study summarized a detailed list containing 1459 reported DILI culprit-drugs and accordingly provided the number of reports and signal detection results related to each drug (Table S2). By contrast, previous studies usually focused on limited single drugs [30,31], single drug classes [32,33], or some drugs with the highest reporting frequency or signal strength [23]. Due to the differences in research methods and time limits, it is difficult to integrate and compare the results of different studies. In this regard, we analyzed 1459 drugs with a unified standard, which broke the barrier of incomparable drug risk results among different studies and facilitated the understanding of potential differences in DILI risks among drugs. Finally, different from other similar studies [21–23], we also pay extra attention to the risk differences between drug classes. In this study, we displayed the most frequently reported drug classes (Fig. 3b) and showed the distribution characteristics of drug risk levels in different drug classes based on the stratifying result of positive signal drugs (Table 2). To our knowledge, there is no similar analysis in




Fig. 3. The top 50 most frequently reported single drugs and drug classes in the FAERS database. (a) The top 50 most frequently reported single drugs; (b) The top 50 most frequently reported drug classes. Note: The classification of drugs is based on the pharmacological or therapeutic subgroup (second level) of the Anatomical Therapeutic Chemical classification system. AIAAA, anti-diarrheals, intestinal anti-inflammatory/anti-infective agents; PCEP, paracetamol combinations excluding psycholeptics.

previous pharmacovigilance studies, and our results add new information for understanding the potential risks of DILI among different drug classes.

Through the comprehensive analysis of AE reports about liver injury in the FAERS database, we also have some new findings. In previous studies, antibiotics, cardiovascular agents, psychotropics, and non-steroidal anti-inflammatory drugs were reported as the main DILI-causative drug classes worldwide [14]. However, our results showed that although some of the representative drugs (e.g. amoxicillin, atorvastatin, quetiapine, and paracetamol) in the above-mentioned drug classes have a place in the most frequently reported single drugs (Fig. 3a), on the whole, antineoplastic agents have replaced them as the most frequently reported drug class leading to DILI (Fig. 3b). Perhaps the sudden emergence of antineoplastic agents can be partly attributed to its huge drug quantity base (Fig. 2b), but some antineoplastic agents (e.g., rituximab, cyclophosphamide, and bevacizumab) are also conspicuous in the ranking of reported quantity (Fig. 3a). Therefore, it is necessary to be more alert to the potential hepatotoxicity of antineoplastic agents in clinical practice and drug safety supervision in the future.

Of course, we also realized that although the high reporting frequency of drugs can reflect their potential hepatotoxicity risk to some extent, the difference in drug use frequency in the real world greatly affects this figure. In the drug epidemiological investigation, incidence is the gold standard to reflect the DILI risk difference between drugs. However, due to a lack of the exact number of patients exposed to drugs and the corresponding number of patients suffering liver injury, it is difficult to determine the actual incidence of DILI caused by each drug to compare the risk differences between drugs. Therefore, in cases where the DILI incidence of most drugs is not available, we introduced the disproportionality analysis as an alternative indicator to evaluate and quantify the potential DILI risk of different drugs. In addition to some notorious hepatotoxic drugs (e.g., isoniazid, rifampicin, and pyrazinamide) showing high risk signals, our results also highlighted that some newly-marketed antineoplastic agents (e.g., vorasidenib ranked first in signal strength) and gene therapy drugs (e.g., delandistrogene moxeparvec ranked fourth in signal strength) may have a high risk of liver injury during medication use (Fig. 4). Vorasidenib is an orally administered, brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase (IDH) 1




Fig. 4. The top 50 drugs with the highest signal strength in the risk detection of liver injury. Note: The classification of drugs is based on the pharmacological or therapeutic subgroup (second level) of Anatomical Therapeutic Chemical classification system. ATC, Anatomical Therapeutic Chemical; CI, confidence interval; DILI, drug-induced liver injury; LTE, lamivudine, tenofovir disoproxil and efavirenz; ROR, reporting odds ratio.

and 2 enzymes, which was first approved for the treatment of adult and pediatric patients aged 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation in the USA on 6 August 2024 [34]. Delandistrogene moxeparvovec is an adeno-associated virus vector-based gene therapy, which was first approved for the treatment of pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy and a confirmed mutation in the dystrophin gene in the USA in June 2023 [35]. In previous clinical trials, vorasidenib and delandistrogene moxeparvovec have been observed to have a significantly higher DILI risk than placebo [36,37], which partly verified the reliability of our results. In recent years, increasing attention has been paid to the

hepatotoxicity of new therapies such as gene therapy and novel anti-neoplastic drugs [17,18], and our study provided additional information for understanding the hepatotoxicity of new therapies from the perspective of post-marketing pharmacovigilance.

Additionally, based on the risk signal detection results (Table S2 and S3), we further summarized the distribution characteristics of 806 positive signal drugs in different drug classes (Table 2). Our results showed that among all drug classes, antineoplastic agents had the largest number (n = 153) of positive signal drugs and occupied a dominant position (9/40) in high-risk (Level A) drugs. In a previous study, Bjornsson ES et al. tried to analyze the hepatotoxicity of different drugs based on LiverTox (<http://livertox.nlm.nih.gov>) [38]. Their

Table 2
The distribution of drug categories of 806 positive signal drugs.

Rank	ATC drug classification	Number of positive signal drugs					Ratio (%) ^a
		Total	A	B	C	D	
1	Antineoplastic agents (L01)	153	9	22	61	61	153/223 (68.61)
2	Antibacterials for systemic use (J01)	65	3	16	28	18	65/74 (87.84)
3	Antivirals for systemic use (J05)	48	6	11	19	12	48/69 (69.57)
4	Psycholeptics (N05)	32	/	/	9	23	32/53 (60.38)
5	Immunosuppressants (L04)	28	/	5	11	12	28/70 (40.00)
6	Psychoanaleptics (N06)	23	/	1	4	18	23/42 (54.76)
7	Drugs used in diabetes (A10)	21	/	1	3	17	21/42 (50.00)
8	Cardiac therapy (C01)	19	1	2	3	13	19/31 (61.29)
9	Agents acting on the renin-angiotensin system (C09)	18	/	/	4	14	18/32 (56.25)
10	Drugs for acid related disorders (A02)	16	1	1	4	10	16/19 (84.21)
11	Antithrombotic agents (B01)	15	/	2	4	9	15/26 (57.69)
12	Antiinflammatory and antirheumatic products (M01)	15	1	1	6	7	15/21 (71.43)
13	Anesthetics (N01)	15	/	/	5	10	15/24 (62.50)
14	Beta blocking agents (C07)	14	/	1	4	9	14/17 (82.35)
15	All other therapeutic products (V03)	14	1	4	3	6	14/29 (48.28)
16	Endocrine therapy (L02)	13	/	5	4	4	13/19 (68.42)
17	Analgesics (N02)	13	/	1	4	8	13/34 (38.24)
18	Other alimentary tract and metabolism products (A16)	12	/	5	4	3	12/36 (33.33)
19	Diuretics (C03)	12	/	2	4	6	12/14 (85.71)
20	Lipid modifying agents (C10)	12	1	1	2	8	12/23 (52.17)
21	Antiepileptics (N03)	12	/	/	1	11	12/23 (52.17)
22	Antimycotics for systemic use (J02)	11	/	6	3	2	11/12 (91.67)
23	Antiprotozoals (P01)	11	/	5	2	4	11/15 (73.33)
24	Antimycobacterials (J04)	10	6	4	/	/	10/10 (100.00)
25	Antihistamines for systemic use (R06)	10	/	/	3	7	10/21 (47.62)
26	Drugs for constipation (A06)	9	/	2	2	5	9/17 (52.94)
27	Vitamins (A11)	9	/	2	1	6	9/11 (81.82)
28	Urologicals (G04)	9	/	1	/	8	9/20 (45.00)
29	Corticosteroids for systemic use (H02)	9	1	/	4	4	9/12 (75.00)
30	Antihypertensives (C02)	8	/	/	1	7	8/13 (61.54)
31	Calcium channel blockers (C08)	8	/	1	2	5	8/9 (88.89)
32	Sex hormones and modulators of the genital system (G03)	8	2	1	3	2	8/30 (26.67)
33	Pituitary and hypothalamic hormones and analogues (H01)	8	1	2	3	2	8/16 (50.00)
34	Drugs for treatment of bone diseases (M05)	7	/	/	3	4	7/9 (77.78)
35	Drugs for obstructive airway diseases (R03)	7	/	/	/	7	7/34 (20.59)
36	Antidiarrheals, intestinal antiinflammatory/antiinfective agents (A07)	6	2	1	/	3	6/10 (60.00)
37	Antihemorrhagics (B02)	6	1	/	/	5	6/10 (60.00)
38	Antianemic preparations (B03)	6	/	/	2	4	6/12 (50.00)
39	Immunostimulants (L03)	6	/	/	2	4	6/15 (40.00)
40	Muscle relaxants (M03)	6	/	/	3	3	6/14 (42.86)
41	Other nervous system drugs (N07)	6	/	1	1	4	6/27 (22.22)
42	Antiemetics and anti-nauseants (A04)	5	/	1	/	4	5/7 (71.43)
43	Blood substitutes and perfusion solutions (B05)	5	/	1	2	2	5/7 (71.43)
44	Mineral supplements (A12)	4	/	/	1	3	4/6 (66.67)
45	Antigout preparations (M04)	4	/	/	1	3	4/5 (80.00)
46	Anthelmintics (P02)	4	/	2	1	1	4/5 (80.00)
47	Nasal preparations (R01)	4	2	1	/	1	4/9 (44.44)
48	Drugs for functional gastrointestinal disorders (A03)	3	/	/	/	3	3/6 (50.00)
49	Antiseptics and disinfectants (D08)	3	/	1	1	1	3/3 (100.00)
50	Thyroid therapy (H03)	3	/	1	1	1	3/4 (75.00)
51	Cough and cold preparations (R05)	3	/	1	1	1	3/7 (42.86)
52	Other respiratory system products (R07)	3	/	1	/	2	3/6 (50.00)
53	Ophthalmologicals (S01)	3	/	/	/	3	3/24 (12.50)
54	Contrast media (V08)	3	/	/	1	2	3/14 (21.43)
55	Bile and liver therapy (A05)	2	1	1	/	/	2/3 (66.67)
56	Digestives, incl. Enzymes (A09)	2	/	/	/	2	2/3 (66.67)
57	Other hematological agents (B06)	2	/	/	1	1	2/9 (22.22)
58	Peripheral vasodilators (C04)	2	/	1	/	1	2/2 (100.00)
59	Antifungals for dermatological use (D01)	2	/	/	1	1	2/5 (40.00)
60	Other drugs for disorders of the musculo-skeletal system (M09)	2	1	/	1	/	2/7 (28.57)
61	Diagnostic agents (V04)	2	/	1	1	/	2/4 (50.00)
62	Therapeutic radiopharmaceuticals (V10)	2	/	/	1	1	2/4 (50.00)
63	Stomatological preparations (A01)	1	/	/	1	/	1/4 (25.00)
64	Anabolic agents for systemic use (A14)	1	/	1	/	/	1/1 (100.00)
65	Antipsoriatics (D05)	1	/	/	1	/	1/2 (50.00)
66	Corticosteroids, dermatological preparations (D07)	1	/	/	/	1	1/2 (50.00)
67	Anti-acne preparations (D10)	1	/	/	1	/	1/3 (33.33)
68	Other dermatological preparations (D11)	1	/	/	/	1	1/7 (14.29)
69	Other gynecologicals (G02)	1	/	/	/	1	1/6 (16.67)
70	Pancreatic hormones (H04)	1	/	/	/	1	1/1 (100.00)
71	Calcium homeostasis (H05)	1	/	/	/	1	1/9 (11.11)

(continued)

Table 2 (Continued)

Rank	ATC drug classification	Number of positive signal drugs					Ratio (%) ^a
		Total	A	B	C	D	
72	Immune sera and immunoglobulins (J06)	1	/	/	1	/	1/4 (25.00)
73	Anti-parkinson drugs (N04)	1	/	/	1	/	1/18 (5.56)
74	Ectoparasiticides (P03)	1	/	1	/	/	1/1 (100.00)
75	Diagnostic radiopharmaceuticals (V09)	1	/	/	1	/	1/6 (16.67)
Total		806	40	121	242	403	806/1459 (55.24)

^a The denominator corresponds to Fig. 2b ATC, Anatomical Therapeutic Chemical.

results showed that although antineoplastic agent have a place in the high-risk drug category, its overall DILI risk ranks behind antimicrobials, drugs acting on the central nervous system, cardiovascular, and rheumatologic. In contrast, our results emphasized the prominent position of antineoplastic agents in many drug classes with potential DILI risk. Moreover, we also found that there are big differences in the specific high-risk DILI drug emphasized. The results of Bjornsson ES et al. mainly suggested the high DILI risk of old antineoplastic agents (e.g. busulfan, floxuridine, and thioguanine) [38], while our study mainly highlighted the high DILI risk of many new generation antineoplastic agents (e.g. vorasidenib, zolbetuximab, and sorafenib). In our opinion, such a difference is largely attributed to the development and application of anti-tumor drugs in recent years, while our results once again emphasized the emerging important role of new antineoplastic agents in DILI. In addition to antineoplastic agents, we also noticed that some classic drug classes with potential hepatotoxicity such as antimycobacterials (10/10, 100.00%), antimycotics for systemic use (11/12, 91.67%), and antibacterials for systemic use (65/74, 87.84%) have a relatively high proportion of positive signal drugs. The above-mentioned results aligned with the known knowledge of hepatotoxicity and also suggested the necessity of continuous attention to the DILI risk of these drug classes during medication use in clinical practice. In general, according to the analysis of the distribution characteristics of positive signal drugs, our study provided a direction for the focus of drug monitoring of DILI culprit-drugs in the future to some extent.

However, although our study provided updated information for clinical practice and drug supervision by a comprehensive analysis of AE reports on liver injury in the FAERS database, several limitations of this study must be mentioned. First, the FAERS database is a pharmacovigilance database with a voluntary reporting nature, and the existence of under-reporting, duplicate reporting, notoriety bias, and Weber effect in the spontaneous reporting database will inevitably damage the accuracy of our data [27]. Second, the reported DILI cases in the FAERS database lack laboratory values, imaging findings, biopsy results, and some other clinical details, which are important for understanding DILI phenotyping and risk drugs involved. Therefore, it is necessary to further verify results presented in this study to enhance diagnostic accuracy and subtype classification by integrating biopsy-confirmed DILI registry data in future study. Third, some disease-induced liver injury may be wrongly attributed to drug-induced and lead to an abnormal increase in the reporting frequency of specific drugs. For example, prednisone ranks fifth in the most frequently reported single drug (Fig. 3a), but it is often used in patients with pre-existing liver inflammation (e.g., autoimmune hepatitis). In this case, the results of drugs with high reporting frequency need to be interpreted cautiously, because it is difficult to completely attribute the reported liver injury to the drug itself. Fourth, in the process of diagnosing DILI, causality assessment scales such as Roussel Uclaf Causality Assessment Method are recommended to establish the causality between drug use and DILI occurrence [39], but the DILI reports submitted to FAERS may not have undergone a similar rigorous assessment, which may lead to the wrong identification of the culprit-

drugs and bring potential result bias. Fifth, multiple factors such as age, sex, polypharmacy, comorbidities, alcohol use, and pre-existing liver disease may increase the risk of DILI [2], but due to the inherent limitations of the FAERS database, it is almost impossible to eliminate the influence of these confounding factors in signal detection. Sixth, the detection results of positive signals only represent the statistical relationship between drug use and liver injury, and whether there is a causal relationship still needs further verification in the clinic. Finally, although the FAERS database receives AE reports from all over the world, the main source is still the United States, so the results obtained from the FAERS database may still not fully represent the global drug use pattern or DILI epidemiology.

5. Conclusions

This study summarized a list of drugs containing 1459 reported potential culprit-drugs by comprehensively reviewing the AE reports related to liver injury in the FAERS database from 2004 to 2024. Based on the summarized list, we made statistics on the most frequently reported single drugs and drug classes and conducted risk signal detection for 1459 drugs respectively. Our results showed that 806 of 1459 drugs have a positive risk signal, suggesting that these drugs have potential DILI risk during medication use. In addition, our results showed that antineoplastic agents occupy a prominent position in reporting frequency of classes, risk signal strength of single drug, number of positive signal drugs, and high-risk drug distribution, suggesting that we may need to pay more attention to the liver injury risk of antineoplastic agents in clinical practice and drug safety supervision in the future.

Funding

This work was supported by the Joint Medical Scientific Research Project of the Chongqing Health Commission and Science and Technology Bureau (2026QNXM023), Research Incubation Project of the Third Affiliated Hospital of Chongqing Medical University (KY24038), Medical research project of Chongqing Municipal Health and Wellness Committee (2025WSJK101), and Key Specialty Construction Project of Clinical Pharmacy in Chongqing.

Author contributions

Conceptualization, D.L. and Q.D.; methodology, D.L. and D.W.; software, D.L.; data curation, D.L., D.W., G.H., Q.L., Y.W. and R.Z.; writing-original draft preparation, D.L.; writing—review and editing, D.L., D.W., G.H., Q.L., Y.W., R.Z., S.L., and Q.D.; visualization, D.L.; funding acquisition, D.L., G.H., and Q.D. All authors have read and agreed to the published version of the manuscript. D.L. is responsible for the integrity of the work as a whole.

Declaration of interests

None.

Supplementary materials

Supplementary material associated with this article can be found in the online version at [doi:10.1016/j.aohep.2025.102156](https://doi.org/10.1016/j.aohep.2025.102156).

References

- Ozturk NB, Uskudar E, Toruner MD, Simsek C, Gurakar A. Drug-induced liver injury: diagnosis, management and the role of liver transplantation. *Hepatol Forum* 2025;6:72–6. <https://doi.org/10.14744/hf.2024.2024.0003>.
- Li X, Tang J, Mao Y. Incidence and risk factors of drug-induced liver injury. *Liver Int* 2022;42:1999–2014. <https://doi.org/10.1111/liv.15262>.
- Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guillemet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. *Hepatology* 2002;36:451–5. <https://doi.org/10.1053/jhep.2002.34857>.
- Suk KT, Kim DJ, Kim CH, Park SH, Yoon JH, Kim YS, et al. A prospective nationwide study of drug-induced liver injury in Korea. *Am J Gastroenterol* 2012;107:1380–7. <https://doi.org/10.1038/ajg.2012.138>.
- Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. *Gastroenterology* 2013;144:1419–25. <https://doi.org/10.1053/j.gastro.2013.02.006>.
- Shen T, Liu Y, Shang J, Xie Q, Li J, Yan M, et al. Incidence and etiology of drug-induced liver injury in mainland China. *Gastroenterology* 2019;156:2230–41. <https://doi.org/10.1053/j.gastro.2019.02.002>.
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: drug-induced liver injury. *J Hepatol* 2019;70:1222–61. <https://doi.org/10.1016/j.jhep.2019.02.014>.
- Chalasanani NP, Maddur H, Russo MW, Wong RJ, Reddy KR. ACG Clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. *Am J Gastroenterol* 2021;116:878–98. <https://doi.org/10.14309/ajg.0000000000001259>.
- Devarbhavi H, Aithal G, Treeprasertsuk S, Takikawa H, Mao Y, Shasthry SM, et al. Drug-induced liver injury: asia Pacific Association of Study of Liver consensus guidelines. *Hepatol Int* 2021;15:258–82. <https://doi.org/10.1007/s12072-021-10144-3>.
- Yu YC, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. *Hepatol Int* 2017;11:221–41. <https://doi.org/10.1007/s12072-017-9793-2>.
- Hosack T, Damry D, Biswas S. Drug-induced liver injury: a comprehensive review. *Therap Adv Gastroenterol* 2023;16:17562848231163410. <https://doi.org/10.1177/17562848231163410>.
- Skat-Rordam J, Lykkesfeldt J, Gluud LL, Tveden-Nyborg P. Mechanisms of drug induced liver injury. *Cell Mol Life Sci* 2025;82:213. <https://doi.org/10.1007/s00018-025-05744-3>.
- Isaacson M, Babich M. Drug-induced liver injury resources and reporting for the clinician. *Clin Liver Dis* 2020;24:131–9. <https://doi.org/10.1016/j.cld.2019.09.010>.
- Low EXS, Zheng Q, Chan E, Lim SG. Drug induced liver injury: east versus West - a systematic review and meta-analysis. *Clin Mol Hepatol* 2020;26:142–54. <https://doi.org/10.3350/cmh.2019.1003>.
- Shin J, Hunt CM, Suzuki A, Papay JI, Beach KJ, Cheetham TC. Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data. *Pharmacoepidemiol Drug Saf* 2013;22:190–8. <https://doi.org/10.1002/pds.3388>.
- Suzuki A, Minjun C. Epidemiology and risk determinants of drug-induced liver injury: current knowledge and future research needs. *Liver Int* 2025;45:e16146. <https://doi.org/10.1111/liv.16146>.
- Chodup P, Samodelov SL, Visentini M, Kullak-Ublick GA. Drug-induced liver injury associated with emerging cancer therapies. *Liver Int* 2025;45:e70002. <https://doi.org/10.1111/liv.70002>.
- Larrey D, Delire B, Meunier L, Zahhaf A, De Martin E, Horsmans Y. Drug-induced liver injury related to gene therapy: a new challenge to be managed. *Liver Int* 2024;44:3121–37. <https://doi.org/10.1111/liv.16065>.
- Lucas S, Ailani J, Smith TR, Abdrabboh A, Xue F, Navetta MS. Pharmacovigilance: reporting requirements throughout a product's lifecycle. *Ther Adv Drug Saf* 2022;13:20420986221125006. <https://doi.org/10.1177/20420986221125006>.
- Moore N, Berdai D, Blin P, Droz C. Pharmacovigilance - the next chapter. *Therapie* 2019;74:557–67. <https://doi.org/10.1016/j.therap.2019.09.004>.
- Brinker AD, Lyndly J, Tonning J, Moeny D, Levine JG, Avigan MI. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database. *Drug Saf* 2013;36:1169–78. <https://doi.org/10.1007/s40264-013-0116-9>.
- Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, Lee WM, Yuen NA, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in Vigibase: unified list based on international collaborative work. *Drug Saf* 2010;33:503–22. <https://doi.org/10.2165/11535340-000000000-00000>.
- Kamimura H, Setsu T, Kimura N, Miyazawa M, Kaneko S, Kamimura K, et al. Analysis of drug-induced liver-related adverse event trend reporting between 1997 and 2019. *Hepatol Res* 2023;53:556–68. <https://doi.org/10.1111/hepr.13883>.
- Fang H, Su Z, Wang Y, Miller A, Liu Z, Howard PC, et al. Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics. *Clin Pharmacol Ther* 2014;95:496–8. <https://doi.org/10.1038/clpt.2014.17>.
- TA Kass-Hout, Xu Z, Mohebbi M, Nelsen H, Baker A, Levine J, et al. OpenFDA: an innovative platform providing access to a wealth of FDA's publicly available data. *J Am Med Inform Assoc* 2016;23:596–600. <https://doi.org/10.1093/jamia/ocv153>.
- Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. *Int J Med Sci* 2013;10:796–803. <https://doi.org/10.1186/1745-7581-10-150>.
- Wang H, Zhong G, Ji H, Chen S, Xie Q, Shen Z, et al. Contrastive analysis on the safety of brand and generic nebulivolol: a real-world pharmacovigilance study based on the FDA adverse event reporting system. *Front Pharmacol* 2024;15:1280201. <https://doi.org/10.3389/fphar.2024.1280201>.
- Bohm R, von Hehn L, Herdegen T, Klein HJ, Bruhn O, Petri H, et al. OpenVigil FDA - inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications. *PLoS One* 2016;11:e0157753. <https://doi.org/10.1371/journal.pone.0157753>.
- Li D, Dai L, Zhu J, Wang Y, Zhang R, Wu F, et al. Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database. *Expert Opin Drug Saf* 2024. <https://doi.org/10.1080/14740338.2024.2396392>.
- Shi A, Nguyen H, Kuo CB, Beringer PM. Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS). *J Cyst Fibros* 2024;23:566–72. <https://doi.org/10.1016/j.jcf.2024.01.001>.
- Yu L, Xiang Q, Liu L. Oseltamivir-induced hepatotoxicity: a retrospective analysis of the FDA adverse event reporting system. *PLoS One* 2025;20:e0314970. <https://doi.org/10.1371/journal.pone.0314970>.
- Jiang A, Wei C, Zhu W, Wu F, Wu B. Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis. *Ther Adv Drug Saf* 2024;15:20420986241244585. <https://doi.org/10.1177/20420986241244585>.
- Sun C, Yang X, Tang L, Chen J. A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system. *Expert Opin Drug Saf* 2024;23:1049–60. <https://doi.org/10.1080/14740338.2023.2277801>.
- Lamb YN. Vorasidenib: first approval. *Drugs* 2024;84:1325–31. <https://doi.org/10.1007/s40265-024-02097-2>.
- Hoy SM. Delandistrogene Moxeparovec: first approval. *Drugs* 2023;83:1323–9. <https://doi.org/10.1007/s40265-023-01929-x>.
- Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. *N Engl J Med* 2023;389:589–601. <https://doi.org/10.1056/NEJMoa2304194>.
- Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Ciafaloni E, Komaki H, et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. *Nat Med* 2025;31:332–41. <https://doi.org/10.1038/s41591-024-03304-z>.
- Bjornsson ES. Hepatotoxicity by drugs: the most common implicated agents. *Int J Mol Sci* 2016;17:224. <https://doi.org/10.3390/ijms17020224>.
- Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. *Int J Mol Sci* 2016;17:14. <https://doi.org/10.3390/ijms17010014>.